Literature DB >> 18686022

Selective alterations of brain dopamine D(2) receptor binding in cirrhotic patients: results of a (11)C-N-methylspiperone PET study.

Yuki Watanabe1, Akinobu Kato, Kei Sawara, Roger F Butterworth, Toshiaki Sasaki, Kazunori Terasaki, Koichiro Sera, Kazuyuki Suzuki.   

Abstract

Alterations of the brain dopamine system have been implicated in the neurological complications of chronic liver failure. The present study was aimed at the measurement of dopamine D(2) binding sites in cirrhotic patients by positron emission tomography (PET) using (11)C-N-methylspiperone as ligand. The regions of interest (ROI) were designated on a three-dimensional stereotaxic ROI template (3DSRT). The pixel values of twelve ROIs corrected by the pixel value of the cerebellum after 80 min static scanning were used to quantitate changes in binding. D(2) binding sites were significantly decreased in the hippocampus and thalamus of cirrhotic patients and were positively correlated with serum bilirubin levels and Child-Pugh scores and were negatively correlated with prothrombin times (thalamus). Loss of D(2) sites was greater in thalamus and hippocampus of alcoholic cirrhotics compared to non-alcoholics. Statistically significant correlations were also observed between D(2) binding sites in hippocampus, thalamus and lenticular nuclei and history of overt encephalopathy. These findings suggest that D(2) receptor binding in some regions of brain in cirrhotic patients is influenced by factors such as the severity of liver damage and history of alcohol dependency or overt encephalopathy. Alterations of D(2) receptor sites indicative of dopaminergic synaptic dysfunction could play an important role in the pathogenesis of the cognitive and motor disturbances associated with chronic liver failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18686022     DOI: 10.1007/s11011-008-9092-7

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  15 in total

Review 1.  The basal ganglia and portal-systemic encephalopathy.

Authors:  K Weissenborn; H Kolbe
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

2.  Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms.

Authors:  L Spahr; R F Butterworth; S Fontaine; L Bui; G Therrien; P C Milette; L H Lebrun; J Zayed; A Leblanc; G Pomier-Layrargues
Journal:  Hepatology       Date:  1996-11       Impact factor: 17.425

3.  Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy.

Authors:  A H Lockwood; E W Yap; H M Rhoades; W H Wong
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

4.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

5.  Different striatal dopamine D2 receptor occupancy in alcohol dependent patients with or without physical withdrawal symptoms --a study using IBZM-SPECT.

Authors:  D Ebert; T Klein; C Lohrmann; L Tebartz van Elst; B Hesslinger; F D Juengling
Journal:  J Neural Transm (Vienna)       Date:  2002-09       Impact factor: 3.575

6.  Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving.

Authors:  Andreas Heinz; Thomas Siessmeier; Jana Wrase; Derik Hermann; Sabine Klein; Sabine M Grüsser; Sabine M Grüsser-Sinopoli; Herta Flor; Dieter F Braus; Hans Georg Buchholz; Gerhard Gründer; Mathias Schreckenberger; Michael N Smolka; Frank Rösch; Karl Mann; Peter Bartenstein
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

7.  Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy.

Authors:  D D Mousseau; P Perney; G P Layrargues; R F Butterworth
Journal:  Neurosci Lett       Date:  1993-11-12       Impact factor: 3.046

8.  Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy.

Authors:  M Y Morgan; A W Jakobovits; I M James; S Sherlock
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

9.  Treatment of chronic hepatic encephalopathy with levodopa.

Authors:  M Lunzer; I M James; J Weinman; S Sherlock
Journal:  Gut       Date:  1974-07       Impact factor: 23.059

10.  Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.

Authors:  M Bergeron; T A Reader; G P Layrargues; R F Butterworth
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

View more
  3 in total

1.  Polysomnographic sleep aspects in liver cirrhosis: a case control study.

Authors:  Vinicius Vasconcelos Teodoro; Mauricio Augusto Bragagnolo; Ligia Mendonça Lucchesi; Daniel Cavignolli; Marco Túlio de Mello; Mario Kondo; Sergio Tufik
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

Review 2.  Alcohol and basal ganglia circuitry: Animal models.

Authors:  David M Lovinger; Veronica A Alvarez
Journal:  Neuropharmacology       Date:  2017-03-21       Impact factor: 5.250

Review 3.  Activators of G-protein signaling 3: a drug addiction molecular gateway.

Authors:  Michael Scott Bowers
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.